Antiaggregants in cardiology: choice of best individual treatment

Abstract

The role of antithrombotic therapy in cardiology has increased substantially over the past decades. On the one hand, mortality causes monitoring, undertaken by certain countries as wellas on the global level under the auspices of the World Health Organization, demonstrate the leading role of thrombosis as a pathogenetic mechanism underlying the majority of premature deaths. The role of this mechanism is revealed by the excellent words of Jens Dedichen (1959): "Man lives with arteriosclerosis, and dies of the complicating thrombosis." [1] On the other hand, the widespread use of antithrombotic therapy is associated not only with the need to prevent both primary and, largely, recurring cardiovascular events, but also with a spread of minimally invasive revascularization techniques. Enovascular interventions the number of which has rapidly grown in in Russia over the past years, became a truly effective and safe treatment thanks to the present-day antithrombotic therapy.

Keywords

• антиагрегантная терапия
• ацетилсалициловая кислота клопидогрел
• тикагрелор
• antiaggregant therapy
• acetylsalicylic acid
• clopidogrel
• ticagrelor